Oxaliplatin-d10
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 464934

CAS#: 1132819-16-9

Description: Oxaliplatin-d10 is intended for use as an internal standard for the quantification of oxaliplatin by GC- or LC-MS. Oxaliplatin is a platinum-containing DNA-crosslinking agent. It induces the formation of DNA inter- and intrastrand crosslinks and DNA-protein adducts, inhibits DNA and RNA synthesis, and induces apoptosis in cancer cells. Oxaliplatin is cytotoxic to cisplatin-sensitive A2780(1A9) and KB-3-1 cells and cisplatin-resistant A2780-E(80) and KB-CP20 cells (IC50s = 0.12, 0.39, 4.7, and 2.7 µM, respectively). It reduces tumor growth in an HCCLM3 mouse xenograft model when administered at doses of 5 or 10 mg/kg once per week. Formulations containing oxaliplatin have been used in the treatment of advanced colorectal cancer and as adjuvants in stage III colon cancer.


Chemical Structure

img
Oxaliplatin-d10
CAS# 1132819-16-9

Theoretical Analysis

MedKoo Cat#: 464934
Name: Oxaliplatin-d10
CAS#: 1132819-16-9
Chemical Formula: C8H4D10N2O4Pt
Exact Mass: 407.1229
Molecular Weight: 407.355
Elemental Analysis: C, 23.59; H, 5.93; N, 6.88; O, 15.71; Pt, 47.89

Price and Availability

Size Price Availability Quantity
1.0mg USD 930.0 2 Weeks
Bulk inquiry

Synonym: Oxaliplatin-d10; Oxaliplatin d10; Lipoxal-d10; Lipoxal d10;

IUPAC/Chemical Name: N/A

InChi Key: ZROHGHOFXNOHSO-YYKMXZQESA-L

InChi Code: InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1/i1D2,2D2,3D2,4D2,5D,6D;;

SMILES Code: O=C1[O-][Pt+2]2([NH2][C@@]([2H])([C@@]3([NH2]2)[2H])C([2H])(C([2H])(C([2H])(C3([2H])[2H])[2H])[2H])[2H])[O-]C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 407.355 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Taieb J, Karoui M, Basile D. How I treat stage II colon cancer patients. ESMO Open. 2021 Jul 5;6(4):100184. doi: 10.1016/j.esmoop.2021.100184. Epub ahead of print. PMID: 34237612.

2: Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, Ranieri G. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers (Basel). 2021 Jun 21;13(12):3091. doi: 10.3390/cancers13123091. PMID: 34205656; PMCID: PMC8234226.

3: Kuo MT, Huang YF, Chou CY, Chen HHW. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy. Pharmaceuticals (Basel). 2021 Jun 8;14(6):549. doi: 10.3390/ph14060549. PMID: 34201235; PMCID: PMC8227247.

4: Zraik IM, Heß-Busch Y. Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen [Management of chemotherapy side effects and their long- term sequelae]. Urologe A. 2021 Jun 29. German. doi: 10.1007/s00120-021-01569-7. Epub ahead of print. PMID: 34185118.

5: Horinouchi T, Yoshida N, Matsumoto C, Hara Y, Toihata T, Iwatsuki M, Baba Y, Miyamoto Y, Baba H. Human Epidermal Growth Factor Receptor 2-positive Primary Adenocarcinoma in the Cervical Oesophagus: A Case Report. In Vivo. 2021 Jul- Aug;35(4):2297-2303. doi: 10.21873/invivo.12503. PMID: 34182509.

6: Zhang B, Zhou F, Hong J, Ng DM, Yang T, Zhou X, Jin J, Zhou F, Chen P, Xu Y. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. World J Surg Oncol. 2021 Jun 21;19(1):182. doi: 10.1186/s12957-021-02291-6. PMID: 34154596; PMCID: PMC8218408.

7: Adams R, Goey K, Chibaudel B, Koopman M, Punt C, Arnold D, Hinke A, Hegewisch-Becker S, de Gramont A, Labianca R, Diaz Rubio E, Magne Tveit K, Wasan H, Kaplan R, Brown L, Maughan T, Fisher D. Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta- analysis. Cancer Treat Rev. 2021 May 19;99:102226. doi: 10.1016/j.ctrv.2021.102226. Epub ahead of print. PMID: 34130171.

8: Boztepe T, Castro GR, León IE. Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. Int J Pharm. 2021 Jun 9;605:120788. doi: 10.1016/j.ijpharm.2021.120788. Epub ahead of print. PMID: 34116182.

9: Gu M, Gao Y, Chang P. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers (Basel). 2021 May 18;13(10):2429. doi: 10.3390/cancers13102429. PMID: 34069772; PMCID: PMC8157241.

10: Ginghină O, Hudiță A, Zaharia C, Tsatsakis A, Mezhuev Y, Costache M, Gălățeanu B. Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials (Basel). 2021 May 8;14(9):2440. doi: 10.3390/ma14092440. PMID: 34066710; PMCID: PMC8125868.

11: Cirri D, Bartoli F, Pratesi A, Baglini E, Barresi E, Marzo T. Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. Biomedicines. 2021 May 4;9(5):504. doi: 10.3390/biomedicines9050504. PMID: 34064364; PMCID: PMC8147839.

12: Lai E, Cascinu S, Scartozzi M. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Front Oncol. 2021 May 10;11:637823. doi: 10.3389/fonc.2021.637823. PMID: 34041019; PMCID: PMC8141840.

13: Branca JJV, Carrino D, Gulisano M, Ghelardini C, Di Cesare Mannelli L, Pacini A. Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect. Front Mol Biosci. 2021 May 7;8:643824. doi: 10.3389/fmolb.2021.643824. PMID: 34026827; PMCID: PMC8138476.

14: Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev. 2021 Jul;98:102218. doi: 10.1016/j.ctrv.2021.102218. Epub 2021 May 4. PMID: 34015686.

15: García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, Soto Alsar J, Torres Pérez-Solero G, Blanco Codesido M, Calvo Ferrandiz PA, Grasso Cicala S. Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2021 Apr 29;13:17588359211009001. doi: 10.1177/17588359211009001. PMID: 33995592; PMCID: PMC8111515.

16: Sugawara K, Kawaguchi Y, Seto Y, Vauthey JN. Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review. Surg Oncol. 2021 May 11;38:101599. doi: 10.1016/j.suronc.2021.101599. Epub ahead of print. PMID: 33991939.

17: Fujisawa A, Takahara H, Kondo Y, Akagami M, Yokoyama T, Takahara N. [A Case of Liver Metastasis of Colorectal Cancer in a Hemodialysis Patient, Underwent Liver Resection and Chemotherapy after Colorectal Resection]. Gan To Kagaku Ryoho. 2021 Apr;48(4):552-554. Japanese. PMID: 33976045.

18: Bijelic L, Ramos I, Goeré D. The Landmark Series: Surgical Treatment of Colorectal Cancer Peritoneal Metastases. Ann Surg Oncol. 2021 Aug;28(8):4140-4150. doi: 10.1245/s10434-021-10049-3. Epub 2021 May 9. PMID: 33969466.

19: Lurvink RJ, Rovers KP, Nienhuijs SW, Creemers GJ, Burger JWA, de Hingh IHJ. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review. J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S242-S258. doi: 10.21037/jgo-20-257. PMID: 33968441; PMCID: PMC8100707.

20: Cashin P, Sugarbaker PH. Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S120-S128. doi: 10.21037/jgo-2020-05. PMID: 33968432; PMCID: PMC8100699.